ACURA PHARMACEUTICALS, INC.
|ACURA PHARMACEUTICALS, INC. Patent applications|
|Patent application number||Title||Published|
|20140336213||Abuse Deterrent Compositions and Methods of Making Same - This invention relates a therapeutic pharmaceutical composition comprising: a mixture including an opioid; polyethylene oxide in an amount of about 3 to about 40 wt % of the composition; a disintegrant; and a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.||11-13-2014|
|20140155388||METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT - An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.||06-05-2014|
|20120039957||OPTIMIZED NIACIN COMPOSITIONS IN PHARMACEUTICAL PRODUCTS - The present invention includes compositions and methods related to forms of niacin with enhanced in-vivo absorption and bioavailability. Such enhanced delivery of niacin in the presence of food may be achieved by size reduction of crystalline niacin, use of amorphous forms of niacin, and/or pH modulation in the presence on organic acids.||02-16-2012|
|20110077238||METHODS AND COMPOSITIONS FOR DETERRING ABUSE - Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.||03-31-2011|
Patent applications by ACURA PHARMACEUTICALS, INC.